Showing 6751-6760 of 7742 results for "".
- FDA Cracks Down on Energy-Based Vaginal Rejuvenationhttps://practicaldermatology.com/news/fda-cracks-down-on-vaginal-rejuvenation/2457667/The FDA is cracking down on the use energy-based devices to perform vaginal 'rejuvenation.' The use of such devices to perform vaginal "rejuvenation," cosmetic vaginal procedures, or non-surgical vaginal procedures to treat symptoms related to menopause, urinary incontin
- SENTÉ Launches Dermal Contour Pressed Serumhttps://practicaldermatology.com/news/sent-launches-dermal-contour-pressed-serum/2457670/Senté's Dermal Contour Pressed Serum with 3 glycosaminoglycan analogs to help tighten skin for a more youthful contour is now availalbe. Patented Heparan Sulfate Analog (HSA) combined with Dermatan Sulfate Analog (DSA) and Chondroitin, Sulfate Analog (CSA), the company's proprietar
- Catch a Sneak Peek of Ground Up Season 2 at Summer AADhttps://practicaldermatology.com/news/get-a-sneak-peek-of-ground-up-season-2-at-summer-aad/2457671/The publishers of Practical Dermatology® and Modern Aesthetics® magazines are offering a sneak peek of the coming new season of the acclaimed video series, Ground Up, at Summer AAD in Chicago. Ground Up Season 1 took viewers
- AAD: Research Shows Free Skin Cancer Screenings Can Help Save Liveshttps://practicaldermatology.com/news/aad-research-shows-free-skin-cancer-screenings-can-help-save-lives/2457675/Data indicates that American Academy of Dermatology’s (AAD's) SPOTme program serves an important need. While skin cancer can be deadly, it is also highly treatable when detected early. In fact, melanoma, the deadliest form of skin cancer, has a five-year survival rate of 95 percen
- Almirall: Phase 3 Studies of KX2-391 for AK Meet Primary Endpointshttps://practicaldermatology.com/news/almirall-phase-3-studies-of-kx2-391-for-ak-meet-primary-endpoints/2457676/Both Phase 3 studies of KX2-391met the primary endpoint of complete clearance of actinic keratosis (AK) lesions at day 57 within the face or scalp treatment areas, Almirall, SA reports. Each study achieved statistical significance on this endpoint. The double-blind, randomized, vehi
- New Applicator Suggests Cryolipolysis May Be an Option for Male Pseudogynecomastiahttps://practicaldermatology.com/news/new-applicator-suggests-cryolipolysis-may-be-an-option-for-male-pseudogynecomastia/2457678/Thanks to a conformable surface applicator, cryolipolysis can be a safe and effective way to treat male pseudogynecomastia, according to a recent study in Lasers in Surgery and Medicine (LSM). “This split-b
- iRestore Expands Reseller Programhttps://practicaldermatology.com/news/irestore-expands-reseller-program/2457677/The iRestore Laser Hair Growth System from Freedom Laser Therapy is now more widely available, thanks to an expanded reseller program for the drug-free, pain-free laser hair restoration device. The reseller program now offers an affiliate model that enables sales representative
- Núria Perez-Cullell Appointed CEO of Pierre Fabre Dermo-Cosmeticshttps://practicaldermatology.com/news/nria-perez-cullell-appointed-ceo-of-pierre-fabre-dermo-cosmetics/2457679/Ms. Núria PerezCullell is the new CEO of The Pierre Fabre Group’s Pierre Fabre Dermo-Cosmetics (PFDC) subsidiary. This appointment will take effect on August 20, 2018. Núria Perez-Cullell will take over from Mr. Eric Ducournau, whose appointment to the position of Pier
- Colorescience Receives Patent for Even Up Clinical Pigment Corrector Formulationhttps://practicaldermatology.com/news/colorescience-receives-patent-for-even-up-clinical-pigment-corrector-formulation/2457687/The US Patent and Trademark Office (USPTO) has granted a patent for Colorescience’s LUMIRA™ formulation, a clinically tested, highly effective complex that addresses the appearance of skin discoloration, found in the 3-in-1 treatment product, Even Up® Clinical Pigment P
- BioPharmX: FDA Grants CARC Waiver; Post-Hoc Analysis for BPX-01 Completehttps://practicaldermatology.com/news/biopharmx-fda-grants-carc-waiver-post-hoc-analysis-for-bpx-01-complete/2457686/The FDA has waived its requirement for a dermal carcinogenicity study for BPX-01 from BioPharmX Corporation, eliminating several years of non-clinical research normally required for FDA review. BPX-01, a novel topical gel formulation of minocycline for the treatment of inflammatory